Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

NCT01114152
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 17, 2026, 4:40 AM EDT
Active, not recruiting Phase 2 Interventional

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03579316
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Adavosertib, Olaparib, Ceralasertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

NCT05590338
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cypress, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+

NCT06148558
View directory record Official record
Conditions
Anti-aging, Photoaging
Interventions
Sunscreen Moisturizer, Gentle Cleansing Lotion, Facial Moisturizer
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newtown Square, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Not applicable Interventional Results available

Resilience Intervention for Older, HIV-Infected Women

NCT03071887
View directory record Official record
Conditions
Resilience, Psychological
Interventions
Relaxation Response Resiliency Program (3RP)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

NCT02480881
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Oral Contraceptive, Loestrin 1.5/30
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 17, 2026, 4:40 AM EDT
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

NCT06732245
View directory record Official record
Conditions
Obesity and Overweight
Interventions
NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Virtual Promotoras Study: eHealth Intervention to Promote Sexual Health Among Young Latina Women in the US South

NCT05632575
View directory record Official record
Conditions
Healthy
Interventions
Virtual Promotoras Program
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
16 Years to 21 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Training in Obesity-prone Black and White Women

NCT00067873
View directory record Official record
Conditions
Obesity
Interventions
Diet, Aerobic exercise, Resistance exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 41 Years · Female only
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Results available

Combined Letrozole and Clomid in Women With Infertility and PCOS

NCT02802865
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Clomiphene, Letrozole
Drug
Lead sponsor
Rachel Mejia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

NCT05169905
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT vaccine, dTpa vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 17, 2026, 4:40 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy

NCT01787994
View directory record Official record
Conditions
HIV
Interventions
Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Not applicable Interventional

Mobile Phone Technology to Increase Genetic Counseling

NCT02877862
View directory record Official record
Conditions
Ovarian Cancer
Interventions
mAGIC app
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

NCT03611569
View directory record Official record
Conditions
Healthy, Parkinson Disease
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Glendale, California • Hollywood, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 17, 2026, 4:40 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 17, 2026, 4:40 AM EDT
Active, not recruiting Phase 1 Interventional

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

NCT03616587
View directory record Official record
Conditions
ER+ HER2- Advanced Breast Cancer
Interventions
AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with abemaciclib, AZD9833 with capivasertib, AZD9833 with ribociclib, AZD9833 with anastrozole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 17, 2026, 4:40 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 17, 2026, 4:40 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes

NCT03718455
View directory record Official record
Conditions
Breast Cancer
Interventions
Axillary Magseed
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Not applicable Interventional Results available

The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study

NCT01272284
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Altis® Single Incision Sling System (SIS)
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Murrieta, California • Hialeah, Florida • Alpharetta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

NCT03613649
View directory record Official record
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 17, 2026, 4:40 AM EDT
Withdrawn No phase listed Observational

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00329017
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine needle aspiration
Procedure
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ACE-083 in Healthy Subjects

NCT02257489
View directory record Official record
Conditions
Musculoskeletal Diseases
Interventions
ACE-083
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
45 Years to 75 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 17, 2026, 4:40 AM EDT